Discussion: irAEs are prevalent side effects of PD-1/PD-L1 inhibitor therapy Nivolumab, pembrolizumab, atezolizumab, durvalumab monotherapy or
www.tga.gov.au/reporting-problems. AUSTRALIAN PRODUCT INFORMATION. IMFINZI. (durvalumab). 1. NAME OF THE MEDICINE. Durvalumab.
Durvalumab patients will be monitored by a healthcare professional while undergoing treatment, in order to evaluate durvalumab side effects and check the patient's response. (6) Because of these factors, durvalumab treatment length is variable, ranging from a few months to years.
Patients were treated with durvalumab in combination with neoadjuvant chemotherapy before radical cystectomy followed by durvalumab as adjuvant monotherapy.
Possible side effects. Many patients do not get any side effects with Durvalumab (Imfinzi). The most common side effects are related to the
Durvalumab in combination with chemotherapy as neoadjuvant treatment, followed by Durvalumab as monotherapy after surgery, is indicated for
Possible Side Effects of Durvalumab Immune Reactions Infection Fatigue Decrease in Appetite Peripheral Edema Allergic Reactions Less common but important
What are the side effects of taking durvalumab? Durvalumab side effects that may occur include fatigue, infection, muscle pain, bone pain, nausea
This phase I trial tests the safety and side effects of yttrium-90 (Y90) radioembolization combined with immunotherapy drugs tremelimumab and durvalumab
Comments